SV2A抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P04480(SV2A Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P04480(SV2A Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The synaptic vesicle glycoprotein 2A (SV2A) is a transmembrane protein ubiquitously expressed in synaptic vesicles of neurons and endocrine cells. As a member of the SV2 family (SV2A, SV2B, SV2C), it plays a critical role in regulating vesicle trafficking, neurotransmitter release, and synaptic plasticity. SV2A is evolutionarily conserved and serves as a biomarker for presynaptic terminals, making it a valuable target for studying synaptic density in neurological disorders.

SV2A antibodies are immunochemical tools developed to detect and quantify SV2A expression. They are widely used in neuroscience research to investigate synaptic alterations in conditions like epilepsy, Alzheimer’s disease, and schizophrenia. Notably, SV2A is the binding target of the antiepileptic drug levetiracetam, highlighting its therapeutic relevance. Antibodies against SV2A enable visualization of synaptic integrity via techniques such as immunohistochemistry, Western blotting, and fluorescence microscopy. Recent advances in SV2A-specific positron emission tomography (PET) ligands further underscore its diagnostic potential.

Due to its consistent expression across brain regions and species, SV2A antibodies serve as reliable markers for comparative studies. Their application extends to evaluating neurodevelopmental processes, drug effects on synaptic networks, and pathological changes in neurodegeneration. This versatility positions SV2A antibodies as essential tools in both basic and clinical neuroscience.